Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 9/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626950 | 0.93 | PIK3C3 (0.39) | PIK3C3TDP1ABL1SMN1; SMN2ADORA3 | |
| SCHEMBL9104878 | 0.86 | JAK1 (0.41) | PIK3C3TDP1ABL1SMN1; SMN2HPGD | |
| SCHEMBL9888652 | 0.86 | PIK3C3 (0.39) | PIK3C3TDP1ABL1SMN1; SMN2HPGD | |
| SCHEMBL16167587 | 0.85 | PIK3C3 (0.40) | PIK3C3TDP1ABL1SMN1; SMN2CNR1 | |
| SCHEMBL9890637 | 0.83 | PIK3C3 (0.41) | PIK3C3TDP1ABL1ADORA3MAPT | |
| SCHEMBL627198 | 0.82 | PIK3C3 (0.39) | PIK3C3TDP1ABL1SMN1; SMN2CNR1 | |
| SCHEMBL9889779 | 0.82 | SMN1; SMN2 (0.40) | PIK3C3TDP1ABL1SMN1; SMN2CNR1 | |
| SCHEMBL626945 | 0.81 | PIK3C3 (0.45) | PIK3C3TDP1ABL1SMN1; SMN2CNR1 | |
| SCHEMBL626067 | 0.80 | PIK3C3 (0.42) | PIK3C3TDP1ABL1SMN1; SMN2CNR1 | |
| SCHEMBL627354 | 0.80 | PIK3C3 (0.43) | PIK3C3TDP1ABL1MAPTPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859768-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142732-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, PIK3C2B, PIK3R1 | PIK3C3 52/4885TDP1 860/4885ABL1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.